AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
![]() CAR-T is one of the most promising fields in medicine and at the end of 2018, there were more than 400 CAR-T trials going around the world.īut for all the promise, the challenges of manufacturing cell therapies are making it hard to deliver the actual treatments. Novartis’s costly manufacturing issues are representative of the state of cell therapy, which includes CAR-T and other treatments where living cells are injected into a patient. Doses that were outside of those specifications couldn’t legally be sold. The company couldn’t consistently manufacture the drug to meet the specifications spelled out in the FDA’s approval. Novartis set its price at US $400,000 per treatment.īut before long, Novartis was simply giving Kymriah away for free to some patients. Like other CAR-T treatments, though, Kymriah is difficult to make and is produced specially for each patient. ![]() ![]() Food and Drug Administration in 2017, it signaled the arrival of CAR-T, a much-hyped form of therapy that proved stunningly effective at curing some hard-to-treat forms of cancer in trials. When Novartis’s cancer treatment Kymriah was approved by the U.S.
0 Comments
Read More
Leave a Reply. |